Latest News

Updated results from Phase 3 trial of IVIG for Alzheimer's disease

Neurologists have reported new findings from the Phase 3 clinical trial of IVIG (intravenous immunoglobulin) in mild to moderate Alzheimer's disease. While the primary study outcomes were negative, observations from the subgroup analyses include whether there may be a dose-dependent reduction of beta amyloid in the blood and brain of IVIG-treated Alzheimer's patients who have the ApoE4 genotype.
View full story

Post your comment.

Name:
Email:
Rating:
Comment:
Verification
 

  • Lead negatively impacts cognitive functions of boys more than girls

  • 'July Effect' doesn?t apply to length of surgery

  • Early English exposure prepares Spanish-speaking children for academic success

  • Brain Secrets Unlocked by International Imaging Effort

  • Estrogen-producing neurons influence aggression in both sexes

  • Secrets of a clump-dissolving protein uncovered

  • Family voices, stories speed coma recovery

  • Prescription painkillers, widely used by childbearing age women, double birth defects risk

  • Low-income boys fare worse in wealth's shadow

  • Tablet computers good medium for educational materials

  •